CD19抗体;CD19 Antibody—艾普蒂

+ +

•  

   

     Immunofluorescence analysis of CD19 in Ramos (positive cell, left) and Jurkat (negative cell, right) using CD19 antibody.    

  
  

•  

   

     Flow Cytometry analysis of Jurkat T cells (black) and Ramos B cells (red), stained with CD19 antibody.    

  
  

CD19 is a transmembrane glycoprotein predominantly expressed on the surface of B cells, serving as a critical regulator of B-cell receptor (BCR) signaling. As a member of the immunoglobulin superfamily, it acts as a co-receptor with CD21 and CD81. modulating B-cell activation, proliferation, and survival. Its restricted expression to B-lineage cells—from pro-B cells to mature B cells, but absent on plasma cells—makes it an attractive therapeutic target for B-cell malignancies and autoimmune disorders.

In oncology, CD19-targeting therapies revolutionized treatment for relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) and non-Hodgkin lymphomas. Chimeric antigen receptor (CAR) T-cell therapies, such as tisagenlecleucel, engineer patient-derived T cells to recognize CD19. achieving remarkable remission rates. Monoclonal antibodies like blinatumomab (bispecific CD19-CD3 antibody) redirect T cells to eliminate CD19+ malignant cells.

Emerging research explores CD19 targeting in autoimmune diseases. By depleting pathogenic autoreactive B cells, CD19-directed therapies show promise in conditions like lupus and rheumatoid arthritis. However, challenges persist, including antigen escape in cancers and prolonged immunosuppression risks. Ongoing studies focus on optimizing efficacy while minimizing toxicity, such as cytokine release syndrome in CAR-T treatments. CD19 remains a cornerstone of B-cell-targeted immunotherapy, with evolving applications across hematology and immunology.